Oak Hill Bio secures funding to develop Angelman syndrome therapy

Oak Hill Bio has launched with backing from RA Capital to compete with established players Ultragenyx and Ionis in the Angelman syndrome therapeutic market. The company's entry signals increased investment in rare neurodevelopmental disease pipelines, though the efficacy of their specific candidate remains unproven.